糖尿病调脂治疗.ppt

2型糖尿病既往无心梗患者和非糖尿病既往有心梗患者风险相似 Framingham Heart Study 30年随访：伴有糖尿病的患者CVD事件 (年龄 35-64) 男性2型糖尿病患者异常脂质水平 女性2型糖尿病患者异常脂质水平 他汀治疗54周对LDL-C和非HDL-C的影响 主要他汀实验中的心血管风险差异 This table summarizes reduction in 10-year risk of major primary CVD prevention endpoints (CHD death/nonfatal MI) in major statin trials, or sub-studies of major trials, in subjects with diabetes Number of patients in both the secondary and primary CVD prevention trials was 16,032 Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI In this tabulation, results of the statin on 10-year risk of major CVD endpoints are listed for comparison between studies Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P=0.0007) NOTE: Analyses provided by Craig Williams, PharmD, Oregon Health Science University, 2007 * References 1. Collins R, Armitage J, Parish S, Sleigh P, Peto R, for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016. 2. Colhoun HM, Betteridge DJ, Durrington PN, et al, for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696. 3. Sever PS, Poulter NR, Dahl?f B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151–1157. 4. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease. Endpoint